Is Gland Pharma overvalued or undervalued?

As of 4 November 2025, Gland Pharma's valuation grade has moved from very expensive to expensive, indicating a shift towards a less extreme valuation. The company is currently considered overvalued, with a PE ratio of 39.73, an EV to EBITDA ratio of 4.64, and a PEG ratio of 2.78. These metrics suggest that Gland Pharma is trading at a premium compared to its peers, particularly when compared to Cipla, which has a PE ratio of 22.35 and an EV to EBITDA of 5.59, and Dr. Reddy's Labs, with a PE of 17.36 and an EV to EBITDA of 10.48. The company's financial performance is further highlighted by a low ROE of 0.83% and a ROCE of 1.40%, which are significantly below industry averages. While Gland Pharma has shown positive returns over the past year at 18.94%, it has underperformed the Sensex over a longer horizon, particularly in the 3-year and 5-year periods. Overall, the combination of high valuation ratios and relatively poor returns suggests that Gland Pharma is overvalued in the current market environment.